A Randomized, Double-blind, Placebo-controlled Single Multiple Dosing, Dose Escalation Phase I Clinical Trial to Investigate HY209 Gel in Healthy Male Volunteers as a Possible Treatment Option for Atopic Dermatitis
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs Taurodeoxycholic-acid (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Shaperon
- 08 Apr 2019 Planned End Date changed from 1 Dec 2018 to 30 Aug 2019.
- 08 Apr 2019 Planned primary completion date changed from 1 Sep 2018 to 30 Jul 2019.
- 16 Apr 2018 New trial record